兴齐眼药：公司已于6月27日完成了“SQ-22031滴眼液Ⅱ期临床试验”首例受试者入组

Group 1 - The company has completed the enrollment of the first subject in the Phase II clinical trial for the innovative drug SQ-22031 on June 27, 2025 [2] - The trial is a randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy of SQ-22031 eye drops in treating neurotrophic keratitis (NK) patients [2]